– Company to Discuss Pipeline of Precision Medicines for Kidney Diseases, Led by Phase 3 Program Atrasentan
VANCOUVER, British Columbia & SEATTLE–(BUSINESS WIRE)–Chinook Therapeutics, Inc. (“Chinook”), a privately held clinical-stage biotechnology company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Eric Dobmeier, President and Chief Executive Officer, will present an overview of the company and its pipeline at the Jefferies Virtual Healthcare Conference at 3:30 p.m. EDT on Wednesday, June 3, 2020.
To access the live webcast and subsequent archived recording of this presentation, please visit the News section of Chinook’s website at www.chinooktx.com. The archived webcast will remain available for replay on Chinook’s website for 90 days.
About Chinook Therapeutics
Chinook Therapeutics, Inc. is a clinical-stage biotechnology company developing precision medicines for kidney diseases. The company’s pipeline is focused on rare, severe chronic kidney disorders with opportunities for well defined and streamlined clinical pathways. Chinook’s lead program is atrasentan, an investigational endothelin receptor antagonist in development for the treatment of primary glomerular diseases. The company is also advancing a 2021 IND candidate for an undisclosed ultra orphan kidney disease and research programs for polycystic kidney disease. Chinook seeks to build its pipeline by leveraging insights in kidney single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with mechanisms of action against key kidney disease pathways. Chinook is backed by leading healthcare investors, Versant Ventures, Apple Tree Partners, and Samsara BioCapital, and is based in Vancouver, BC and Seattle, WA. For more information visit www.chinooktx.com.
Contacts
Ian Stone
Canale Communications
(619) 849-5388
ian@canalecomm.com
Linda Hernández, miembro de la Junta Directiva de HITN, recibirá el reconocimiento Silver Circle 2025…
Joint Venture Partner Committed Annual Profit of RMB80 Million and 50% Annual Growth SHANGHAI, Feb.…
Vancouver, British Columbia--(Newsfile Corp. - February 21, 2025) - Metavista3D Inc. (TSXV: DDD) (FSE: E3T)…
FIRST SINGLE “MULTIPLE” AVAILABLE NOW VINYL + CD Via WAXWORK PRE-ORDER NOW ALBUM ART (FOR…
BEIJING, Feb. 21, 2025 /PRNewswire/ -- A news report from China.org.cn on the Chinese blockbuster "Ne…
An Immersive VR App With A Groundbreaking Catalog of Your Favorite Songs to Sing Along…